Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$69.8 million.

  • Aclaris Therapeutics' Cash from Investing Activities rose 394.81% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year decrease of 291.39%. This contributed to the annual value of -$69.8 million for FY2024, which is 250.95% down from last year.
  • As of FY2024, Aclaris Therapeutics' Cash from Investing Activities stood at -$69.8 million, which was down 250.95% from $46.2 million recorded in FY2023.
  • Aclaris Therapeutics' 5-year Cash from Investing Activities high stood at $46.2 million for FY2023, and its period low was -$167.6 million during FY2021.
  • Over the past 3 years, Aclaris Therapeutics' median Cash from Investing Activities value was $12.6 million (recorded in 2022), while the average stood at -$3.6 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Cash from Investing Activities crashed by 2,724.58% in 2021 and then surged by 266.01% in 2023.
  • Aclaris Therapeutics' Cash from Investing Activities (Yearly) stood at $6.4 million in 2020, then crashed by 2,724.58% to -$167.6 million in 2021, then spiked by 107.53% to $12.6 million in 2022, then skyrocketed by 266.01% to $46.2 million in 2023, then plummeted by 250.95% to -$69.8 million in 2024.